Regeneron Prescription drugs, Inc. (NASDAQ:REGN) is included among the many 13 Firms that Simply Began Paying Dividends.
In the course of the This autumn 2025 earnings name, CEO Leonard Schleifer mentioned Regeneron Prescription drugs, Inc. (NASDAQ:REGN) delivered regular income progress. Fourth-quarter gross sales rose 3% from a yr earlier. He mentioned the rise got here from double-digit progress throughout three key merchandise.
International web gross sales of DUPIXENT climbed 32%. LIBTAYO gross sales elevated 13% on a constant-currency foundation. Within the U.S., EYLEA HD stood out, with gross sales up 66%. Schleifer pointed to that efficiency as a transparent signal of momentum, notably within the home market.
He described DUPIXENT as a core pillar of the enterprise. The drug is now utilized by greater than 1.4 million sufferers worldwide and stays positioned for additional progress. Schleifer additionally highlighted progress at LIBTAYO, citing power in adjuvant CSCC and rising share in superior non-small cell lung most cancers. Within the U.S., he mentioned the remedy has grow to be the second most prescribed immunotherapy within the first-line setting.
Trying forward, Schleifer laid out a busy regulatory and growth agenda. He mentioned the corporate expects not less than 4 FDA approvals, together with three new molecular entities throughout totally different modalities, together with approval of the EYLEA HD prefilled syringe.
He additionally famous plans to launch 18 extra Section III research over the approaching years, with whole enrollment of about 35,000 sufferers. In accordance with Schleifer, the dimensions of funding is meant to assist the following wave of potential blockbuster merchandise.
Regeneron Prescription drugs, Inc. (NASDAQ:REGN) is a completely built-in biotechnology firm that invents, develops, manufactures, and commercializes medicines for individuals with critical ailments.
Whereas we acknowledge the potential of REGN as an funding, we imagine sure AI shares provide better upside potential and carry much less draw back danger. For those who’re on the lookout for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory.
READ NEXT: 13 Finest February Dividend Shares To Purchase and 14 Excessive Yield Dividend Shares with Sustainable Payouts
Disclosure: None.
